Pearl E. Grimes MD, FAAD
Director, Vitiligo and Pigmentation Institute of Southern California; Clinical Professor, Division of Dermatology, David Geffen School of Medicine, University of California, Los Angeles, CaliforniaDr. Pearl Grimes is the Founder and Director of the Vitiligo and Pigmentation Institute of Southern California. She is a pioneer and a leading international authority on vitiligo and pigmentary disorders. Dr. Grimes is a Clinical Professor of Dermatology at the David Geffen School of Medicine, University of California – Los Angeles. She has authored more than 100 professional articles, abstracts and two textbooks. Dr. Grimes holds numerous achievements in dermatology. She has been recognized by her peers with the prestigious Dermatology Foundation “Practitioner of the Year” award and the Women’s Dermatologic Society’s “Mentor of the Year” award and the American Society of Dermatologic Surgery President’s Award in 2006. In 2016, she was recognized with an American Skin Association Research Achievement Award. She was also awarded the prestigious 2017 Arnold P. Gold Foundation Humanism in Medicine Award and the 2017 Everett C. Fox, MD Memorial Award and Lectureship. In addition, she was the recipient of the prestigious Lifetime Achievement Award from the American Skin Association for 2017.She is an active member of multiple professional organizations including: The American Academy of Dermatology, The American Society of Dermatologic Surgery, the American Dermatological Association, Society of Investigative Dermatology, the Dermatology Foundation, International Federation of Pigment Cell Societies, International Peeling Society, & the Women’s Dermatologic Society. Dr. Grimes was the President of the Women’s Dermatologic Society for 2018-2019. She has been included in LA Magazine’s Super Doctors list and the Best Doctors of America list for many years.
Disclosures
Dr. Grimes has done clinical research for and/or served as a consultant for: Galderma, Allergan, Procter & Gamble, Clinuvel, Merz, L'Oreal, Johnson & Johnson, LaserOptek,Therapeutics, VT Technologies, Incyte, Pfizer, and Dermaforce.Recent Contributions to PracticeUpdate:
- Outcomes of Treatment With Oral Melatonin in Patients With Recalcitrant Melasma
- African American Race Is a Risk Factor for Severe Hidradenitis Suppurativa
- A Review of Current Phase III Clinical Trials of Plaque Psoriasis
- Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo